Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
77studies shown
Showing 26-50 of 77
RecruitingISRCTN99520723

Sex differences in interoception and mental health: an investigation across the menstrual cycle

This study is recruiting. It focuses on anxiety and currently lists participation information in the United Kingdom, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, and Sweden.

AnxietyOtherFrom 18 Years to 40 Years
Countries
United Kingdom, Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
Sponsor
University of Surrey
Condition
Anxiety
RecruitingISRCTN12329547

Trial of a digital depression management application: juli

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom, Afghanistan, Finland, Albania, Algeria, the United States, Andorra, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, the Netherlands, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Norway, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Congo, Democratic Republic, New Zealand, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Vatican City, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, North Korea, South Korea, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Federated States of, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Macedonia, Oman, Pakistan, Palau, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, the Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkmenistan, Tuvalu, Turkey, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Western Sahara, Yemen, Zambia, and Zimbabwe.

DepressionOtherFrom 18 Years to 65 Years
Countries
United Kingdom, Afghanistan, Finland, Albania, Algeria, United States, Andorra, Angola, Antarctica, Antigua and Barbuda, Argentina, Armenia, Netherlands, Australia, Austria, Azerbaijan, Bahamas, Bahrain, Bangladesh, Barbados, Belarus, Belgium, Belize, Benin, Bhutan, Bolivia, Bosnia and Herzegovina, Botswana, Norway, Brazil, Brunei Darussalam, Bulgaria, Burkina Faso, Burundi, Cabo Verde, Cambodia, Cameroon, Canada, Central African Republic, Chad, Chile, China, Colombia, Comoros, Congo, Congo, Democratic Republic, New Zealand, Costa Rica, Croatia, Cuba, Cyprus, Czech Republic, Côte d'Ivoire, Denmark, Djibouti, Dominica, Dominican Republic, Ecuador, Egypt, El Salvador, Equatorial Guinea, Eritrea, Estonia, Eswatini, Ethiopia, Fiji, France, Gabon, Gambia, Georgia, Germany, Ghana, Greece, Grenada, Guatemala, Guinea, Guinea-Bissau, Guyana, Haiti, Vatican City, Honduras, Hungary, Iceland, India, Indonesia, Iran, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Kenya, Kiribati, North Korea, South Korea, Kosovo, Kuwait, Kyrgyzstan, Lao People's Democratic Republic, Latvia, Lebanon, Lesotho, Liberia, Libya, Liechtenstein, Lithuania, Luxembourg, Madagascar, Malawi, Malaysia, Maldives, Mali, Malta, Marshall Islands, Mauritania, Mauritius, Mexico, Micronesia, Federated States of, Moldova, Monaco, Mongolia, Montenegro, Morocco, Mozambique, Myanmar, Namibia, Nauru, Nepal, Nicaragua, Niger, Nigeria, North Macedonia, Oman, Pakistan, Palau, Palestine, State of, Panama, Papua New Guinea, Paraguay, Peru, Philippines, Poland, Portugal, Qatar, Romania, Russian Federation, Rwanda, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Samoa, San Marino, Sao Tome and Principe, Saudi Arabia, Senegal, Serbia, Seychelles, Sierra Leone, Singapore, Slovakia, Slovenia, Solomon Islands, Somalia, South Africa, South Sudan, Spain, Sri Lanka, Sudan, Suriname, Sweden, Switzerland, Syria, Taiwan, Tajikistan, Tanzania, Thailand, Timor-Leste, Togo, Tonga, Trinidad and Tobago, Tunisia, Turkmenistan, Tuvalu, Turkey, Uganda, Ukraine, United Arab Emirates, Uruguay, Uzbekistan, Vanuatu, Venezuela, Vietnam, Western Sahara, Yemen, Zambia, Zimbabwe
Sponsor
University College London
Condition
Depression
RecruitingISRCTN03693000

GENome-based therapeutic drugs for DEPression

This study is recruiting. It focuses on depression and currently lists participation information in the United Kingdom, Belgium, Croatia, Denmark, Germany, Italy, Poland, and Slovenia.

DepressionOtherOver 18 Years
Countries
United Kingdom, Belgium, Croatia, Denmark, Germany, Italy, Poland, Slovenia
Sponsor
European Commission (Belgium)
Condition
Depression
RecruitingISRCTN68736636

The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in first episode schizophrenia with different low dose antipsychotic drug regimens

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, the Netherlands, Poland, Romania, Spain, Sweden, and Switzerland.

SchizophreniaOtherOver 18 Years
Countries
Austria, Belgium, Bulgaria, Czech Republic, France, Germany, Israel, Italy, Netherlands, Poland, Romania, Spain, Sweden, Switzerland
Sponsor
European Group for Research in Schizophrenia (EGRIS) (Austria)
Condition
Schizophrenia
RecruitingISRCTN83240263

The MILESTONE study: improving transition from child to adult mental health care

This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United Kingdom, Belgium, Croatia, France, Germany, Ireland, Italy, and the Netherlands.

SchizophreniaOther
Countries
United Kingdom, Belgium, Croatia, France, Germany, Ireland, Italy, Netherlands
Sponsor
University of Warwick
Condition
Schizophrenia
RecruitingISRCTN15109760

Implementing digital mobile mental health in routine care

This study is recruiting. It focuses on mental health and currently lists participation information in the United Kingdom, Belgium, Germany, and Slovakia.

Mental healthOtherFrom 14 Years to 64 Years
Countries
United Kingdom, Belgium, Germany, Slovakia
Sponsor
Central Institute of Mental Health
Condition
Mental health
CompletedEUCTR 2022-000439-22

A Randomized, Double-blind, Multicenter, Parallel-Group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants ...

This study is completed. It focuses on depression and currently lists study information in Sweden, Czech Republic, Spain, Hungary, Belgium, Bulgaria, Portugal, Poland, and View results.

DepressionOther
Countries
Sweden, Czech Republic, Spain, Hungary, Belgium, Bulgaria, Portugal, Poland, View results
Sponsor
Janssen-Cilag International NV
Condition
Depression
OngoingEUCTR 2022-000430-42

An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

This study is ongoing. It focuses on depression and currently lists study information in Sweden, Hungary, Belgium, Czech Republic, Poland, Bulgaria, France, Spain, Portugal, and Slovakia.

DepressionOther
Countries
Sweden, Hungary, Belgium, Czech Republic, Poland, Bulgaria, France, Spain, Portugal, Slovakia
Sponsor
Janssen-Cilag International NV
Condition
Depression
CompletedEUCTR 2020-000341-14

A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in ...

This study is completed. It focuses on depression and currently lists study information in Czech Republic, the United Kingdom, Lithuania, Latvia, Belgium, Bulgaria, Poland, Slovakia, and View results.

DepressionOther
Countries
Czech Republic, United Kingdom, Lithuania, Latvia, Belgium, Bulgaria, Poland, Slovakia, View results
Sponsor
Janssen-Cilag International NV
Condition
Depression
CompletedEUCTR 2015-003578-34

An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression

This study is completed. It focuses on depression and currently lists study information in Germany, the United Kingdom, Belgium, Spain, Poland, Hungary, Czech Republic, Slovakia, Lithuania, Austria, Finland, Bulgaria, Italy, and View results.

DepressionOther
Countries
Germany, United Kingdom, Belgium, Spain, Poland, Hungary, Czech Republic, Slovakia, Lithuania, Austria, Finland, Bulgaria, Italy, View results
Sponsor
Janssen-Cilag International NV
Condition
Depression
OngoingEUCTR 2018-000821-29

A Phase 4, Multicenter, 2-part Study Composed of a 1-Year Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-comparator, Dose-optimization Evaluation followed by a 1-Year Open-lab...

This study is ongoing. It focuses on ADHD and currently lists study information in Germany, the Netherlands, Sweden, Austria, Spain, Belgium, Portugal, and the United Kingdom.

ADHDOther
Countries
Germany, Netherlands, Sweden, Austria, Spain, Belgium, Portugal, United Kingdom
Sponsor
Takeda Development Center Americas, Inc.
Condition
ADHD
OngoingEUCTR 2020-003745-11

An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)

This study is ongoing. It focuses on schizophrenia and currently lists study information in France, Czech Republic, Spain, Slovakia, Hungary, Norway, Denmark, Lithuania, Italy, Greece, Belgium, Sweden, the Netherlands, Finland, Croatia, Austria, Bulgaria, Portugal, and Romania.

SchizophreniaOther
Countries
France, Czech Republic, Spain, Slovakia, Hungary, Norway, Denmark, Lithuania, Italy, Greece, Belgium, Sweden, Netherlands, Finland, Croatia, Austria, Bulgaria, Portugal, Romania
Sponsor
Boehringer Ingelheim
Condition
Schizophrenia
CompletedNCT01076361

Model 4968 CAPTURE EPI® STERIOD-ELUTING BIPOLAR EPICARDIAL PACING LEAD Post-approval Study

This study is completed. It focuses on bipolarity and currently lists study information in Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, the Netherlands, Serbia and Montenegro, Spain, Sweden, Switzerland, and the United States.

BipolarityOther
Countries
Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Serbia and Montenegro, Spain, Sweden, Switzerland, United States
Sponsor
Medtronic
Condition
Bipolarity
Enrolling By InvitationNCT07546526

VR-relaxation for ECT-related Anxiety

This study is enrolling by invitation. It focuses on anxiety and currently lists participation information in Belgium.

AnxietyOtherFrom 18 Years to 75 Years
Countries
Belgium
Sponsor
Universitair Ziekenhuis Brussel
Condition
Anxiety
TerminatedNCT06635135

A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure

This study has public registry information. It focuses on depression and currently lists study information in Argentina, Belgium, Brazil, Bulgaria, France, Germany, Greece, Mexico, Poland, Romania, Spain, Turkey, and the United States.

DepressionOtherFrom 18 Years to 64 Years
Countries
Argentina, Belgium, Brazil, Bulgaria, France, Germany, Greece, Mexico, Poland, Romania, Spain, Turkey, United States
Sponsor
Janssen Research & Development, LLC
Condition
Depression